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Abstract
Background: Head and neck cancers (HNC) constitute 5–8% of total body cancers in Europe and
America. It is difficult to appreciate the problem of cancers in Nigeria because most studies
available are hospital-based studies. The aim of this study is to highlight current evidence on the
burden of head and neck cancers in Nigeria based on literature review and to discuss potential
health care actions to improve management.
Methods: A literature search using Medline was conducted for publications on head and neck
cancer in Nigeria. Identified publications were manually searched for additional relevant non-
Medline articles or abstracts. The full-texts of these articles were thoroughly examined for the
occurrence, distribution, identified risks factors, presentations, diagnostic method, treatment,
prognosis and challenges associated with the management of HNC.
Results: A total of twenty-seven relevant published articles on Head and neck cancers from 1968
to 2008 were reviewed. The age of patients with HNC ranged from nine months to over 80 years
with peak between 3–6th decade of life. The male to female ratio ranged from 1:1 to 2.3:1. Identified
risks factors were scanty, namely kola nuts and tobacco chewing, tobacco smoking, farming, viral
infections, alcohol and smoking. Reports on the overall pattern of Head and neck cancers from
different regions of the country cited nasopharynx as the commonest site for HNC, the sino-nasal
is the second commonest while larynx, is the third commonly affected site. The majority of HNC
was epithelial in origin and was mostly squamous cell carcinoma. Late presentation with advanced
disease is common and treatment in most cases is palliative either with surgery or chemotherapy,
and radiotherapy when available. There are few reports on the outcome of HNC treatment in
Nigeria.
Conclusion: The burden of managing HNC in Nigeria is enormous and the government should
set up the National Cancer Institute with a view of educating the public on cancer prevention,
detection and treatment.
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Introduction
Head and neck cancers (HNC) constitute 5–50% of all
cancers globally [1], and 5–8% of total body cancers in
Europe and America [2-4]. In India, HNC constitutes
about 30% of all cancers [5]. In some part of Northern
Nigeria, a yearly hospital incidence of 20–24 new cases
has been reported [6,7] while in southern part of the
country HNC form 6.2% of all cancers [8]. In South-west-
ern Nigeria a yearly incidence of 33–38 new cases has
been reported [9,10]. Nigeria is a developing country in
Africa and its people are of the Negroid race. Nigeria has a
population of 140 million persons and a land area of
923,768.64 sq. kilometers [11]. There are six geopolitical
zones in the country and all the states in the country have
primary, secondary and tertiary health care institutions.
Major occupations in Nigeria include agricultural, admin-
istrative jobs, manufacturing, white-collar professional
jobs and various artisan jobs. Mining which is limited to
few areas of the country is poorly developed [11].
Occurrence of cancers at various sites in the body differs
from one place to another even in the same country
[6,7,9,10]. Aetiological factors associated with cancers
vary according to major risk factors in different geograph-
ical areas and between genders [7,9,12,13]. As demo-
graphic factors change, the pattern of cancers in a place
may also change.
It is difficult to appreciate the problem of cancers in
Nigeria because there is lack of comprehensive data and
most studies available are hospital-based studies. There
are no community based or population based database,
previous studies were region-based and not nation-based
and most of these reports are retrospective. A clearer
understanding of the patterns of cancers will assist provid-
ers of health care as they plan the management of cancers.
Such epidemiological data and other information can also
be used to guide the future funding of public health pro-
grammes geared towards prevention and management of
cancers.
The aim of this study is to highlight current knowledge on
the burden of head and neck cancers in Nigeria and to dis-
cuss potential health care actions to improve prevention
and treatment.
Methods
A literature search using Medline was conducted for pub-
lications on head and neck cancers in Nigeria. The rele-
vant references in the identified publications were
manually searched for other additional relevant non-
Medline articles or abstracts. Personal contacts were also
made with authors of previous studies for the provision of
articles found suitable for the review. The full-texts of all
of these articles were thoroughly examined by the authors
for the occurrence, distribution, identified risks factors,
presentations, diagnostic method, treatment, prognosis
and challenges associated with the management of HNC.
Results
A total of 27 relevant published articles on head and neck
cancers from 1968 to 2008 were reviewed. Ten of them
were on the pattern of head and neck cancers from differ-
ent regions [6-10,12,14-18] (Additional file 1), while oth-
ers were on specific sites namely nasopharynx, sino-nasal,
larynx, oral cavity and salivary glands from different
regions[13,19-34] (Additional file 2).
Epidemiology
A review of the published literature from Nigeria showed
that the age of patients ranged between nine months to
over 80 years [6-10,12,13,19-35]. It is known generally
that cancers are diseases of the elderly. But reports from
Jos and Maiduguri in Northern Nigeria [6,8,14] show a
peak incidence in the 3rd and 4th decades, those from
Lagos (South west) and Ilorin (North central) [10,16]
reported a peak incidence in the 4th to 5th decades while
reports from Ibadan (South west) Nigeria [12,18] showed
a peak incidence in the 6th decade of life. The peak age of
incidence of Nasopharyngeal malignancies in most
reports from Nigeria was found in the 4th decade of life
[9,10,15,21,16-23]. However, a bimodal curve was
reported from Jos (North central) and Lagos (South west)
with the first peak in the 2nd decade and the second peak
in the 4th and 5th decade [21-23]. Laryngeal cancers had a
peak incidence in the 5th decade in South-western cities of
Lagos and Ibadan [10,28], while in northern city of Jos
[26] the mean age was 46.5 years with peak incidence in
the 4th decade. The peak age occurrence of maxillary can-
cer was in the 4th decade in Jos [24] and in the 5th decade
and the 6th to 7th decades in two different reports from
Lagos [10,25]. A recent study from Lagos showed that the
peak age of incidence of oral cancer in Lagos was in the 5th
decade of life [29]. In this study the age of patients ranged
from 2.5 to 85 years, and 25% of the cases were found in
patients below the age of 40 years [29]. A review of squa-
mous cell carcinoma of the oral cavity in Lagos found the
peak incidence in the 20 to 29-year and 40 to 49-year age
groups, with 40% cases occurring in patients under age of
40 years [30]. The mean age of occurrence of salivary
gland tumours in Enugu and in Lagos was 40 years [32-
34].
In most studies from Nigeria, HNC affected more males
than females [6,8,10,12,14,15,17,35,36], except a study
from Ilorin (North central) [16], where females were
affected more than males. The male to female ratio ranged
from 1:1 to 2.3:1 [6,8,10,12,14-16,29,30,36].Head & Neck Oncology 2009, 1:14 http://www.headandneckoncology.org/content/1/1/14
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Aetiological Factors
Identified risks factors among the reviewed articles
included: kola nuts, tobacco, farming, viral infections,
alcohol and smoking [7,9,12,13,23,26,35]. In a report
from Maiduguri [7] northern region of the country,
tobacco smoking, tobacco chewing and chewing of kola
nuts were associated with carcinoma of oral cavity. Kola
nuts (Cola acuminate) has been reported to promote pal-
atal mucosa keratinization of cigarette smokers and is
considered a co-carcinogen. Laryngeal cancer was com-
moner in patients who consumed alcohol than smokers
in the report from Jos [26], while in reports from Enugu
[35], Lagos [13] and Ile Ife [9] most patients with laryn-
geal carcinoma were non-smokers. Virus is thought to be
responsible for some HNC in sero-positive patients by
viral oncogenesis. Nwaorgu et al [12] reported that sali-
vary gland malignancy was the commonest tumour in
patients with HIV sero-positivity in Ibadan (South-west)
while Otoh et al [7] reported Kaposi sarcoma as the most
common tumours in these patients in North-eastern
Nigeria.
Tumour Sites
Reports on the overall pattern of Head and neck cancers
from different regions of the country cited nasopharynx as
the commonest site [7,8,10,12,14,15] (Additional file 3).
The nose and paranasal sinuses were the second most
common reported sites [7,10,12,14] while larynx, was the
third commonly affected site [8,10,14,17]. In contrast,
Amusa et al [9] and Otoh et al [7] reported differently that
malignancy of the oral cavity was the commonest in Ile-Ife
(South-west) and Maiduguri (North central) Nigeria.
Ologe et al [16] and Otoh et al [7] reported that thyroid is
not an uncommon site of HNC. A review on commonest
sites of oro-facial malignancy from Lagos, noted the man-
dible, maxilla, palate, tongue, cheek, lip and floor of the
mouth [29,30] as the most commonly affected sites.
Tumours of the oropharynx, hypopharynx, skin and eye
were also seen but in low in prevalence in some reports
[7,8,10,12,14-17]. A recent study [18] from Ibadan
(South-west) reported that oral cavity and oropharyx were
the most commonly affected sites accounting for 31.1% of
cases, followed by nasopharynx (16.4%) and nose/para-
nasal sinuses (15%). Cancers of the ear was notably few
[7-9,14,17]. Unknown metastatic neck nodes was
reported in some of the series [7,9,10,12,15,16].
Tumour Type
The majority of HNC was epithelial in origin and was
mostly squamous cell carcinoma (SCC) [7-10,14-16,18].
SCC constituted 66.7% of all epithelial tumours in a
recent study from Ibadan (South-west), Nigeria. Lympho-
mas were the second most frequent cell type seen in many
centres [6,7,9,14,15]. Nwawolo et al in Lagos, Lilly-Tariah
in Jos and Okoye et al in Port-harcourt found sarcomas to
be the second most occurring histologic type [8,10,17].
The two most common head and neck cancers in Ibadan
were SCC, which accounted for 47.8% of all cases, fol-
lowed by lymphomas which accounted for 19.3% [18]. By
contrast, Amusa et al [9] found that lymphoma was the
most frequently diagnosed head and neck cancer,
accounting for 40.3%, whereas SCC only accounted for
25% of cases. Ajayi et al [29] from Lagos reported epithe-
lial malignant tumours (69%), mostly SCC as the most
common orofacial malignant tumours followed by sarco-
mas (18%) and lymphomas (13%).
Presentation, Diagnosing and Staging
Few studies reported on the clinical presentations and
staging of head and neck tumours [7,13,23,25,26]. Late
presentation of the advanced disease was a common fea-
ture in most reports from different parts of Nigeria.
[7,13,19,20,22,23,25,26]. By the TNM classification of
tumours, only 1 study reported stage 1 tumours among all
the studied reports [13]. Stage II cancers were few and the
reported sites were larynx and nasopharynx [7,13,22,27].
Most reports were on stages III and IV and the reported
sites were larynx, nasopharynx and maxillary antrum
[7,13,19,20,25,27].
Treatment and Outcome
There are few reports on the treatment and outcome of
HNC in Nigeria [7,13,15,19,20,22,23,25,27]. Otoh et al
[7] in North central Nigeria reported that radiotherapy,
surgery and chemotherapy were the main therapeutic
modalities for carcinoma, sarcoma and lymphoma
respectively. In their study, radiotherapy was used in
41.7%, surgery 39.6%, combination of radiotherapy/sur-
gery in 11.4% and chemotherapy in 7.3% [7], however,
treatment outcome was not reported. Iseh and Malami
[15] reported that surgery and chemotherapy were the
main treatment modalities in Sokoto (North-west,
Nigeria), and adduced non availability of radiotherapy in
the region and the logistics of assessing the radiotherapy
facility as the reasons for the treatment modalities in the
report. Report on laryngeal carcinoma treatment in South
western Nigeria [13] showed 86.1% of patients had radi-
otherapy, 2.7% had laryngectomy and 8.3% received a
combination of surgery and radiotherapy. Of these cases
[13] 47.3% of the patients were lost to follow up less than
two years, 16.7% after two years, 22.2% were dead after
two years of treatment of which 5.6% were unrelated to
the carcinoma. Recurrence rate after 2 years was 16.7%.
Alive and disease free 4 years post-treatment was 5.6%.
Treatment modality for laryngeal carcinoma from North
central Nigeria [27], showed that 31.5% had total larynge-
ctomy, 20.4% were inoperable and were referred for radi-
otherapy and 48% refused surgery. Almost all the patients
were lost to follow up after 1 year [27]. Radiotherapy is the
mainstay of nasopharyngeal carcinoma [21] except whereHead & Neck Oncology 2009, 1:14 http://www.headandneckoncology.org/content/1/1/14
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such is not available [15,19,20,23]. Lilly-Tariah et al [24]
on report on treatment of naso-antral carcinoma from
north western Nigeria: 33.3% had surgery (hemimaxillec-
tomy/frontoethmoidectomy), 41.7% had chemotherapy
alone, and 5.6% received a combination of radiotherapy
and chemotherapy. Management of maxillary antral carci-
nomas as reported by Ogunlewe et al [25] in Lagos (South
west, Nigeria) included hemi-maxillectomy and radio-
therapy in 68.2% of cases, hemi-maxillectomy/orbital
exenteration and radiotherapy in 10.53% of patients, and
radiotherapy and chemotherapy in 13.6% of cases. After 2
years, recurrence rate was 5.3%, death due to the disease
occurred in 10.5% of cases and 84.2% was lost to follow
up during the period.
Discussion
Historical perspectives
One of the earliest references to any head and neck cancers
in Nigeria was the work of Elmes and Baldwin [36] who
reported cases of nasopharyngeal cancer but noted that it
was rare. Edington and Gilles (1965), and Edington and
Maclean (1965) also reported cases of oesophageal carci-
noma and salivary gland tumours respectively and found
them to be rare in Nigeria [31,37]. The work of Martinson
in Ibadan in 1968 showed that cancer of the nasopharynx
was not so uncommon as previously reported [19]. The
pioneering work of Okafor in South-eastern Nigeria
pointed to malignant tumours being rare in the HNC
[35]. He did however, noted that all the cases presented
late to the hospital [35].
University College Hospital (UCH) Ibadan was the first
teaching hospital in Nigeria, and is also the first hospital
to be equipped with radiotherapy unit and Computed
Tomography-scan facility among other facilities. The
effect of this is that all across the country, patients were
referred to Ibadan for diagnosis and irradiation therapy
for a long period of time. The first cancer registry was also
established in 1960 in UCH, Ibadan [20]. The diagnosis
and management of HNC rests on the head and neck sur-
geons and the pathologists. There are currently less than
200 Ear, Nose and Throat Head/Neck surgeons, less than
250 pathologists and less than 30 radiation oncologist
and clinical therapist practicing in the country. In addi-
tion, there are fewer than 50 practicing Oral and Maxillo-
facial Surgeons in the country. All these are insufficient for
a population of over 140 million people.
It is difficult to appreciate the problem of cancers in
Nigeria because most studies available are hospital-based
studies [21]. There are no community based or popula-
tion based database. Most of the reports are retrospective
and a lot of the data might have been lost.
Epidemiology
Overall, Head and Neck Cancers seem to affect Nigerians
at a younger age than in Caucasians. This is in keeping
with reports from other African studies [38,39]. The rea-
sons for higher percentage of occurrence in younger age
group in Nigeria are not so clear but they may be con-
nected to issues of race, genetics, poverty and behavioral
practices. Shorter life expectancy in Africans compared
with Caucasians, and earlier exposure to risk factors have
also been speculated [29]. However, it has also been
reported that oral squamous cell carcinoma (SCC) is now
on the increase in younger age groups in United Kingdom
and USA [40].
There is male preponderance in most studies of HNC
worldwide [41-43] in agreement with reports from
Nigeria. The reason for this is not obvious. In Nigeria,
males and females are exposed to the same factors. There
are preferences in activities but these are not exclusive.
Men consume more alcohol and tobacco than females. It
is possible that hormonal factors may play a significant
role.
Aetiological Factors
The role of alcohol and tobacco in carcinogenesis is well
documented [4,44,45]. Nigerians smoke cigarettes but
not as much as in the western world. In all the studies,
there was no proven direct relationship with smoking.
Alcohol is more indigenous and its usage is more wide-
spread. Carcinoma of the larynx when it occurs in non-
smokers has been found to be biologically aggressive [13].
The role of the Epstein Barr virus and human papilloma
virus in HNC are well documented in the literature
[44,45], but no such study has been reported in Nigeria.
The role of hard wood dust in adenocarcinoma of the
nose and paranasal sinuses, nickel and chromate dust in
the larynx, nose and paranasal sinuses and hydrocarbons
in HNC are well known [4,44,45] but these were not
determined in all the studies so far. As Nigeria continues
to industrialize, the role of these agents in carcinogenesis
cannot be ignored.
Tumour sites
A diversity of cancers of anatomical sites is included under
the broad group "head and neck cancer" by various
authors. For example, Onyango et al [41] included eye
and thyroid cancers. Nwawolo et al [10] included neither
cervical esophageal, thyroid nor eye malignancies in this
group of lesions. Adeyemi et al [18] did not separate oral
cancers from oropharyngeal cancers in their reports. How-
ever, most reports across the country confirms nasophar-
ynx, sinus-nasal and larynx, as the commonly affected
sites of HNC in Nigeria [10,12,14-17] while the reported
pattern in Kenya was Larynx, oral cavity and nasopharynx
[43].Head & Neck Oncology 2009, 1:14 http://www.headandneckoncology.org/content/1/1/14
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Tumour Type
SCC was the most prevalent histologic type in most of the
reports from Nigeria [10,12,14-18] This is in agreement
with the literature worldwide [41-45]. However, 2 studies
reports from Nigeria have reported lymphomas as the
most common HNC cancers followed by squamous cell
carcinoma [6,9].
Regional Differences
The population and land size of Nigeria is large and the
customs and practices are just as varied. The climatic con-
ditions from one place to the other also vary. In the rural
areas the people are largely indigenous to the area. In the
urban centres this is not quite the case as this is a melting
point of all Nigerians. There are tertiary/teaching hospitals
in all the geo-political zones of the country and head and
neck surgeons are available in all of them. These hospitals
are in the urban and semi-urban areas, and funding and
provision of diagnostics facilities is the prerogative of the
federal government. The reports from various centres
across the country as reviewed in the present study are
hardly a true reflection of the cancer pattern of any partic-
ular tribe or groups. The nature of the studies such as the
study design (mostly retrospective in nature), small sam-
ple size and short duration of study are some of the factors
that make it difficult to make out any clear-cut disease pat-
tern. There were more similarities than differences in the
pattern of HNC across the country. The observed minor
differences could hardly be said to be due to geographical
difference. In a report from Ibadan [18], nasopharyngeal
cancers were the most common HNC. In contrast, studies
from Ilorin and Ile-Ife reported nasal/paranasal cancers
and oral cancers as the most frequently occurring HNC
respectively. In addition, in the same center, patterns may
vary at different times; the first study in Jos [6] identified
neck lymphomas as the most common HNC, whereas a
later work [8] showed nasopharyngeal cancer to be the
commonest. The import of this is that there is a need for a
large scale national survey on the incidence, aetiology,
pattern of presentation, management and prognosis of
Head and Neck Cancers. These research questions are best
answered by either a longitudinal, cohort or a case-control
study [46].
Diagnosing and Staging
Cancers are known to occur more often with increasing
age [40,45]. The presenting features will depend on the
primary site of the disease. Sometimes the lesion is so
gross that it is difficult to determine the primary source.
One common feature of HNC is unknown primary lesion.
The early symptoms of HNC are usually vague and non-
specific. Because these symptoms do not produce func-
tional limitation or cosmetic problems, they are often
ignored or not suspected. A lot of primary physicians are
not familiar with these lesions. In this part of the world,
patients consulting traditional healers and spiritual faith
healers tend to contribute to needless delays.
Sadly, most patients in our environment present at
advanced stage of the [7,13,31]. Ignorance, poverty and
lack of trained personnel (ENT surgeons, maxillofacial
surgeons, general surgeons, and family physicians) to
make proper diagnosis and referral contribute to the dis-
mal state of late presentation. The diagnosis of HNC
requires a good knowledge of the disease pattern and a
high index of suspicion. Some sites of HNC like larynx,
pharynx and maxillary antrum are not readily visible or
palpable requiring examination under anaesthesia. Video-
endoscopic examination of mucosal surfaces, imaging
technique, multiple biopsies of suspected primary sites
and histological diagnosis are some of the requirements
for diagnosis. The skill and material for these are not read-
ily available in most of the hospitals of first contact. CT
scan and MRI are revolutionary tools for radiologic diag-
nosis and determination of the extent of treatment and
the progress of the disease. A total of about thirty CT scan-
ner machines and about fifteen MRI machines are availa-
ble across the country, and about 70% of these are located
in the southern part of the country. Till date, considerable
distances, sometimes over 500 kilometres, have to be cov-
ered to get to a center that has a functioning CT scan and
MRI facilities.
The advent of immunohistochemistry and immunocyto-
chemistry has also revolutionized the histological diagno-
sis of head and neck Cancers. Differentiation of poorly
differentiated or anaplastic carcinoma from histological
subtypes of sarcomas and lymphomas may require immu-
nohistochemical staining [47]. However, facilities for this
special staining technique are not readily available in
most centres across the country [7].
Treatment
Surgery, radiotherapy and chemotherapy either alone or
in combination are the standard modalities of treatment
of HNC [48,49]. The histologic cell type and the stage of
the disease determine the choice of treatment. Lympho-
mas respond satisfactorily to chemotherapy. Early stages
of head and neck carcinomas can be treated satisfactorily
(cured) with radiotherapy alone or surgery alone. Stages
III and IV carcinomas require a combination of salvage
surgery and radiotherapy [48]. Radiotherapy maybe used
before or after surgery [45,49]. Chemotherapy is also use-
ful in cases of metastasis and recurrence. Chemotherapy
may also be used for induction chemotherapy before radi-
otherapy [48]. Frozen section is a standard procedure to
ascertain safety or otherwise of tumour margins in most
centres around the world. In Nigeria, frozen sections are
not routinely done in the management of HNC.Head & Neck Oncology 2009, 1:14 http://www.headandneckoncology.org/content/1/1/14
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Outcome of Treatment
There are few reports on the outcome of HNC treatment
in Nigeria. Most patients in this environment present at
hospitals at a late stage of the disease [22,27]. Treatment
at this stage is largely palliative and not curative. This cer-
tainly carries a poor prognosis. High drop-out rate is
another problem in this environment. The reasons
include poverty, ignorance, and difficulty in getting the
appropriate attention from the few personnel available,
long distances to the health centers and the high cost of
drugs when they are available. Treatment of cancers in
Nigeria was free about 2 decades ago but that has changed
and the patients most of whom are poor have to pay for
these expensive and scarce drugs [21]. Complications
from treatment following surgery, radiotherapy or chem-
otherapy are many and can be severe. Over dosage (>50–
59 Grays) maybe a cause of morbidity and mortality [22],
while under-dosage may be a cause for early recurrence
and mortality.
Other Medical Conditions
Chronic liver, lung and heart diseases may affect manage-
ment of HNC. In addition, chronic alcohol usage maybe
a factor in the management and aetiology of HNC [45].
Diabetes mellitus, hypertension and HIV/AIDS are
endemic conditions that affect the management of HNC.
These conditions call for a multidisciplinary approach.
Funding the Burden
The burden of managing HNC is enormous. Annually,
more than 10 million persons are diagnosed with cancer
[21]. More than half of these persons are in the develop-
ing world [21]. The World Health Organization (WHO)
estimates that 12.5% of all deaths worldwide are due to
cancer. This is greater than HIV/AIDS, malaria and tuber-
culosis combined [21,46,50]. The disease is on the
increase and the peak incidence involves the active work-
ing class. The diagnosis of HNC is capital intensive. Only
the Government, the WHO, International Atomic Energy
Agency (IAEA) and such organizations can bear this cost.
This involves planning, quality control programme, train-
ing of manpower and putting in place the necessary infra-
structures. In a situation where only 5% of cytotoxic drugs
get to the developing world, which has 50% of all cancers,
only governments can intervene. There are five function-
ing radiotherapy centers in Nigeria today with a popula-
tion of over 140 million of which three are located in the
south west, one in the middle belt and one in the north.
This comes to one radiotherapy unit to 30 million persons
as against the WHO recommendation of 1 to 250,000 per-
sons [21]. It has only recently been estimated that it costs
about $100 billion a year to treat patients with cancers
overseas [51].
Prospects for the Future
Head and neck cancers are not uncommon in Nigeria.
Reports from centers across the country showed that can-
cers of the nasopharynx, sinonasal and larynx are the most
frequently seen. Most patients present late for diagnosis
and treatment; and subsequently prognosis of HNC in our
environment is poor. The WHO reported that a third of all
cancers are preventable, and therefore prevention pro-
grammes target at reducing the incidence of cancers
should be given a priority by the appropriate authority.
There must be planning and the political will to enforce
the plans. There must be an effective National Cancer Reg-
istry. Without the statistics on HNC, it will be impossible
to plan meaningfully. The government should set up the
National Cancer Institute with a view to educating the
public on cancer prevention, detection and treatment.
There should be a policy on training more head and neck
surgeons, pathologists, radiation oncologist and clinical
therapist and other support staff. The challenges of HNC
are enormous and the governments at various levels must
take active part in intensive public enlightenment cam-
paign aimed at reducing the incidence and burden of head
and neck cancers. Finally, it would be of great benefit if a
population-based study were undertaken to determine
the national incidence of head and neck cancer in Nigeria.
Most of the data available in the literature are based on
hospital studies that are difficult to relate to the general
population. Longitudinal and cohort studies are also
needed to identify possible risk factors for the develop-
ment of cancer of the head and neck region in our popu-
lation.
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